Analyst Ratings For Circassia Pharmaceuticals PLC (LON:CIR)
Today, Peel Hunt reiterated its Under Review rating on Circassia Pharmaceuticals PLC (LON:CIR).
There are 2 Hold Ratings, 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Circassia Pharmaceuticals PLC (LON:CIR) is Buy with a consensus target price of GBX 106.25 per share, a potential .
Some recent analyst ratings include
- 2/1/2019-Circassia Pharmaceuticals PLC (LON:CIR) had its Under Review rating reiterated by Peel Hunt
- 9/27/2018-Circassia Pharmaceuticals PLC (LON:CIR) had its Buy rating reiterated by Numis Securities with a GBX 140 price target
- 4/25/2017-Circassia Pharmaceuticals PLC (LON:CIR) had its Buy rating reiterated by Stifel Nicolaus with a GBX 150 price target
About Circassia Pharmaceuticals PLC (LON:CIR)
Circassia Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of respiratory diseases. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; and Tudorza for the treatment of chronic obstructive pulmonary disease (COPD). Its pipeline products include Flixotide, Seretide, and Flovent for asthma; and various novel specialty for COPD treatments, such as Duaklir, Spiriva, Novel LABA/LAMA formulation, and novel COPD therapy formulation. The company has a collaboration agreement with AstraZeneca to promote Tudorza and for COPD treatment, and has the United States commercial rights to COPD therapy Duaklir. It markets its products directly to specialists in the United States, the United Kingdom, and Germany, as well as through a network of partners in China, Japan, Europe, and internationally. Circassia Pharmaceuticals plc was founded in 2006 and is headquartered in Oxford, the United Kingdom.
Recent Trading Activity for Circassia Pharmaceuticals PLC (LON:CIR)
Shares of Circassia Pharmaceuticals PLC closed the previous trading session at 41,88 −0,82 1,92 % with 26.84 shares trading hands.